ACADIA Pharmaceuticals Inc. (ACAD): Today's Featured Drugs Winner

ACADIA Pharmaceuticals was a winner within the drugs industry, rising $1.79 (9.7%) to $20.28 on average volume
By TheStreet Wire ,

ACADIA Pharmaceuticals

(

ACAD

) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.9%. By the end of trading, ACADIA Pharmaceuticals rose $1.79 (9.7%) to $20.28 on average volume. Throughout the day, 5,425,644 shares of ACADIA Pharmaceuticals exchanged hands as compared to its average daily volume of 3,676,900 shares. The stock ranged in a price between $18.45-$20.43 after having opened the day at $18.67 as compared to the previous trading day's close of $18.49. Other companies within the Drugs industry that increased today were:

ImmunoCellular Therapeutics

(

IMUC

), up 15.1%,

Ambit Biosciences

(

AMBI

), up 11.6%,

Neostem

(

NBS

), up 9.4% and

Nymox Pharmaceutical Corporation

(

NYMX

), up 9.2%.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. ACADIA Pharmaceuticals has a market cap of $1.6 billion and is part of the health care sector. Shares are up 299.1% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate ACADIA Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates ACADIA Pharmaceuticals as a

sell

. Among the areas we feel are negative, one of the most important has been weak operating cash flow.

On the negative front,

Mast Therapeutics

(

MSTX

), down 35.9%,

Tranzyme

(

TZYM

), down 6.9%,

Biostar Pharmaceuticals

(

BSPM

), down 6.2% and

Prima Biomed

(

PBMD

), down 6.1% , were all laggards within the drugs industry with

Alexion Pharmaceuticals

(

ALXN

) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

Loading ...